<DOC>
	<DOC>NCT01310166</DOC>
	<brief_summary>The purpose of this study is to investigate which changes in immunological biomarkers under treatment with fingolimod in patients with relapsing-remitting multiple sclerosis can be detected.</brief_summary>
	<brief_title>Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>Subjects with relapsing forms of MS defined by 2005 revised McDonald criteria Patients with Expanded Disability Status Scale (EDSS) score of 06.5 Patients with a manifestation of MS other than relapsing remitting MS Patients with a history of chronic disease of the immune system other than MS such as known immunodeficiency syndrome History or presence of malignancy in the last 5 years Diabetic patients with moderate or severe nonproliferative diabetic retinopathy or proliferative diabetic retinopathy and uncontrolled diabetic patients Diagnosis of macular edema during Screening Phase Patients with active systemic bacterial, viral or fungal infections Negative for varicellazoster virus IgG antibodies at Screening Patients who have been treated with cladribine, cyclophosphamide or mitoxantrone at any time History of cardiovascular disorder Women of childbaring potential and inadequate contraception Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Multiple sclerosis</keyword>
	<keyword>RRMS</keyword>
	<keyword>relapsing-remitting</keyword>
	<keyword>fingolimod</keyword>
	<keyword>biomarkers</keyword>
</DOC>